Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.430
+0.080 (2.39%)
Apr 17, 2026, 9:45 AM EDT - Market open

Editas Medicine Revenue

In the year 2025, Editas Medicine had annual revenue of $40.52M with 25.39% growth. Editas Medicine had revenue of $24.74M in the quarter ending December 31, 2025, a decrease of -19.16%.

Revenue (ttm)
$40.52M
Revenue Growth
+25.40%
P/S Ratio
8.09
Revenue / Employee
$465,747
Employees
87
Market Cap
335.70M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202540.52M8.21M25.39%
Dec 31, 202432.31M-45.81M-58.64%
Dec 31, 202378.12M58.41M296.32%
Dec 31, 202219.71M-5.83M-22.83%
Dec 31, 202125.54M-65.19M-71.85%
Dec 31, 202090.73M70.20M341.93%
Dec 31, 201920.53M-11.41M-35.71%
Dec 31, 201831.94M18.21M132.64%
Dec 31, 201713.73M7.68M126.80%
Dec 31, 20166.05M4.42M271.58%
Dec 31, 20151.63M--
Dec 31, 2014---

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Cellectis79.59M
Zentalis Pharmaceuticals26.87M
LENZ Therapeutics19.09M
Abeona Therapeutics5.82M
AC Immune4.51M
Surrozen3.48M
Revenue Rankings